Critical Contrast: TRACON Pharmaceuticals (TCON) versus Mateon Therapeutics (MATN)

TRACON Pharmaceuticals (NASDAQ: TCON) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for TRACON Pharmaceuticals and Mateon Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TRACON Pharmaceuticals 0 0 1 0 3.00
Mateon Therapeutics 0 1 1 0 2.50

TRACON Pharmaceuticals presently has a consensus price target of $8.00, suggesting a potential upside of 201.89%. Mateon Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 352.28%. Given Mateon Therapeutics’ higher possible upside, analysts clearly believe Mateon Therapeutics is more favorable than TRACON Pharmaceuticals.

Earnings and Valuation

This table compares TRACON Pharmaceuticals and Mateon Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TRACON Pharmaceuticals $8.76 million 5.37 -$19.10 million ($1.14) -2.32
Mateon Therapeutics N/A N/A -$13.81 million ($0.52) -0.43

Mateon Therapeutics has lower revenue, but higher earnings than TRACON Pharmaceuticals. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TRACON Pharmaceuticals and Mateon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TRACON Pharmaceuticals -201.21% -82.47% -47.74%
Mateon Therapeutics N/A -802.11% -384.06%

Risk & Volatility

TRACON Pharmaceuticals has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.

Institutional & Insider Ownership

74.6% of TRACON Pharmaceuticals shares are owned by institutional investors. 23.3% of TRACON Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply